肝病患者与肝移植受者接种COVID-19疫苗后的免疫应答与临床结局
该研究在四国招募849名参与者(包括肝硬化、自身免疫性肝炎、血管性肝病、肝移植受者及健康对照),纵向评估1至3剂COVID-19疫苗接种后的SARS-CoV-2特异性T细胞和抗体应答,并长期随访COVID-19相关临床结局。结果显示肝病患者接种三剂后抗体和T细胞应答良好且COVID-19病情轻微,但肝移植受者抗体滴度持续低/无且似乎最易发生重症。
要点
- 肝病患者接种三剂COVID-19疫苗后抗体和T细胞应答良好,突破性COVID-19病情轻微。
- 肝移植受者抗体滴度持续低/无,似乎最易发生重症突破性感染。
- 肝病患者对Omicron亚型的功能性抗体应答和T细胞应答低于野生型。
核心结论
- 接种三剂COVID-19疫苗后,肝病患者通常产生稳健的抗体和T细胞应答,COVID-19病情轻微;但肝移植受者抗体滴度持续低/无,似乎最易发生重症。
研究设计与样本
- 研究招募849名参与者,包括355例肝硬化、74例自身免疫性肝炎(AIH)、36例血管性肝病(VLD)、257例肝移植受者(LTR)和127例健康对照(HC),来自四个国家。
- 在接种三剂疫苗(V1-3)前后进行标准化免疫检测。
主要发现
- 总队列中,每剂疫苗接种后抗体滴度递增增加(p<0.0001)。
- 与抗体应答降低相关的因素为年龄和肝移植,而异源疫苗接种、既往COVID-19和mRNA平台与更强的应答相关。
- 尽管抗体滴度在第二剂后至第三剂前下降(p=0.012),AIH、VLD和肝硬化患者在第三剂后抗体应答与HC相当。
- LTR抗体滴度低于其他组且异质性更大,第三剂后9%无可检测抗体,这受免疫抑制强度严重影响。
- 疫苗接种增加所有组的T细胞IFNγ应答,但LTR除外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Comparative assessments of immunogenicity following different COVID-19 vaccines in patients with distinct liver diseases are lacking. SARS-CoV-2-specific T-cell and antibody responses were evaluated longitudinally after one to three vaccine doses, with long-term follow-up for COVID-19-related clinical outcomes. METHODS: A total of 849 participants (355 with cirrhosis, 74 with autoimmune hepatitis [AIH], 36 with vascular liver disease [VLD], 257 liver transplant recipients [LTRs] and 127 healthy controls [HCs]) were recruited from four countries. Standardised immune assays were performed pre and post three vaccine doses (V1-3). RESULTS: In the total cohort, there were incremental increases in antibody titres after each vaccine dose (p <0.0001). Factors associated with reduced antibody responses were age and LT, whereas heterologous vaccination, prior COVID-19 and mRNA platforms were associated with greater responses. Although antibody titres decreased between post-V2 and pre-V3 (p = 0.012), patients with AIH, VLD, and cirrhosis had equivalent antibody responses to HCs post-V3. LTRs had lower and more heterogenous antibody titres than other groups, including post-V3 where 9% had no detectable antibodies; this was heavily influenced by intensity of immunosuppression. Vaccination increased T-cell IFNγ responses in all groups except LTRs. Patients with liver disease had lower functional antibody responses against nine Omicron subvariants and reduced T-cell responses to Omicron BA.1-specific peptides compared to wild-type. 122 cases of breakthrough COVID-19 were reported of which 5/122 (4%) were severe. Of the severe cases, 4/5 (80%) occurred in LTRs and 2/5 (40%) had no serological response post-V2. CONCLUSION: After three COVID-19 vaccines, patients with liver disease generally develop robust antibody and T-cell responses to vaccination and have mild COVID-19. However, LTRs have sustained no/low antibody titres and appear most vulnerable to severe disease. IMPACT AND IMPLICATIONS: Standardised assessments of the immune response to different COVID-19 vaccines in patients with liver disease are lacking. We performed antibody and T-cell assays at multiple timepoints following up to three vaccine doses in a large cohort of patients with a range of liver conditions. Overall, the three most widely available vaccine platforms were immunogenic and appeared to protect against severe breakthrough COVID-19. This will provide reassurance to patients with chronic liver disease who were deemed at high risk of severe COVID-19 during the pre-vaccination era, however, liver transplant recipients had the lowest antibody titres and remained vulnerable to severe breakthrough infection. We also characterise the immune response to multiple SARS-CoV-2 variants and describe the interaction between disease type, severity, and vaccine platform. These insights may prove useful in the event of future viral infections which also require rapid vaccine development and delivery to patients with liver disease.
引用
- Murray SM, Pose E, Wittner M, et al. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients. J Hepatol. 2023. PMID: 37863203. doi:10.1016/j.jhep.2023.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。